Quidelortho Corporation (DE:QL1A)
NASDAQ:QL1A
Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.02Last Year’s EPS
0.1Same Quarter Last Year
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a mixed picture: near-term headwinds were significant (a ~30% weaker respiratory season, an 8% decline in labs revenue, quarter-level margin and cash flow pressure, and China distributor pauses), but management emphasized strategic progress—completion of the Lex acquisition, new product launches (troponin, VITROS 450), cost actions, and a full-year plan targeting a 23% adjusted EBITDA margin and positive free cash flow of $100M–$120M. Given the company’s proactive mitigation steps, clear product and pipeline catalysts, and multi-pronged margin initiatives versus the material but largely contextual short-term revenue and cash setbacks, the tone is balanced between caution on near-term execution risks and optimism on medium-term recovery and margin improvement.Company Guidance
Completed Lex Diagnostics Acquisition
Acquired Lex Diagnostics (April 2026) adding an ultrafast molecular point-of-care platform; secured initial customer orders, expecting to place a few hundred instruments in 2026 with measurable assay pull-through and associated revenue beginning in early 2027; expanding UK manufacturing capacity to support ramp.
Product Launches and Commercial Traction
Launched high-sensitivity troponin assay in the U.S., now shipping to more than 300 U.S. customers; began rollout of VITROS 450 (CE Mark secured) targeting JAPAC then LATAM/EMEA to support international labs growth; these launches expected to support mid-single-digit revenue growth in the labs business (labs = >50% of revenue).
Q1 Revenue and Non-Respiratory Mix
Total reported Q1 revenue was $620 million with non-respiratory revenue of $552 million ($544 million excluding donor screening), demonstrating diversified revenue streams outside of the respiratory shortfall.
Immunohematology Growth
Immunohematology revenue grew 3% year-over-year, driven by performance in North America, China, and JAPAC.
Cost Discipline and Opex Efficiency
Non-GAAP operating expenses decreased 2% in Q1 driven by R&D efficiencies; company has taken significant cost actions historically (~1,000 positions removed) and outlined procurement, facility consolidation (Raritan shutdown), and targeted staff reductions to drive margin expansion.
Full-Year Profitability and Cash Guidance
Updated full-year 2026 guidance expects adjusted EBITDA of $615 million to $630 million (~23% adjusted EBITDA margin, +100 bps vs 2025), adjusted diluted EPS $0.80 to $2.00, and positive free cash flow of $100 million to $120 million for the year.
Strong Working Capital Actions and FX Tailwind
Delivered strong accounts receivable collections of $54 million in Q1 and reduced CapEx by $22 million versus prior-year; foreign currency was favorable by 210 basis points in the quarter.
DE:QL1A Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:QL1A Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | €9.75 | €9.75 | +0.02% |
Feb 11, 2026 | €23.80 | €23.80 | 0.00% |
Nov 05, 2025 | €23.60 | €24.60 | +4.24% |
Aug 05, 2025 | €20.40 | €22.40 | +9.80% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Quidelortho Corporation (DE:QL1A) report earnings?
Quidelortho Corporation (DE:QL1A) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is Quidelortho Corporation (DE:QL1A) earnings time?
Quidelortho Corporation (DE:QL1A) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Quidelortho Corporation stock?
The P/E ratio of QuidelOrtho is N/A.
What is DE:QL1A EPS forecast?
DE:QL1A EPS forecast for the fiscal quarter 2026 (Q2) is -0.02.
